Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677548 | PMC |
| http://dx.doi.org/10.1001/jamaneurol.2021.3933 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Amyloid precursor protein as a fibrosis marker in infants with biliary atresia.
Pediatr Res
September 2024
Department of Respiratory and Infectious Medicine, Hannover Medical School, Hannover, Germany.
Background: Biliary atresia (BA) is a rare condition of unknown origin in newborns with jaundice. In BA bile ducts are non-functional, causing neonatal cholestasis and following liver fibrosis and failure.
Methods: This retrospective study included liver biopsies of 14 infants with BA aged [mean ± SD] 63 ± 23 days.
Cerebral Superficial Siderosis : Etiology, Neuroradiological Features and Clinical Findings.
Clin Neuroradiol
June 2023
Institute of Neuroradiology (1), Goethe University, Schleusenweg 2-16, 60528, Frankfurt am Main, Germany.
Superficial siderosis (SS) of the central nervous system constitutes linear hemosiderin deposits in the leptomeninges and the superficial layers of the cerebrum and the spinal cord. Infratentorial (i) SS is likely due to recurrent or continuous slight bleeding into the subarachnoid space. It is assumed that spinal dural pathologies often resulting in cerebrospinal fluid (CSF) leakage is the most important etiological group which causes iSS and detailed neuroradiological assessment of the spinal compartment is necessary.
View Article and Find Full Text PDFAducanumab: Appropriate Use Recommendations Update.
J Prev Alzheimers Dis
May 2022
Jeffrey Cummings, MD, ScD, 1380 Opal Valley Street, Henderson, NV 89052, USA, T: 702-902-3939.
Aducanumab (Aduhelm) is approved in the United States for the treatment of patients with mild cognitive impairment due to Alzheimer's disease or mild AD dementia. Aducanumab Appropriate Use Recommendations (AURs) have been published and have helped guide best practices for use of aducanumab. As real-world use has occurred and more information has accrued, the AURs require refinement.
View Article and Find Full Text PDFAmyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review.
JAMA Neurol
March 2022
Neurology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.
Importance: After more than a decade of research and development of clinical trials testing anti-β-amyloid monoclonal antibodies (mAbs), extensive experience has been gained regarding the effects of these treatments in patients with Alzheimer disease (AD). On the verge of an expected large-scale introduction in the clinical setting after the recent US Food and Drug Administration approval of aducanumab, shared knowledge regarding amyloid-related imaging abnormalities (ARIAs) is of paramount importance.
Objective: To summarize available evidence on ARIAs from randomized clinical trials (RCTs) testing anti-β-amyloid mAbs in patients with AD and to provide a comprehensive update about risk factors, clinical correlates, and implications for withholding and reinitiating treatment.
Six Recurrent Amyloid-Related Imaging Abnormality Episodes in a Patient Treated With Aducanumab.
JAMA Neurol
January 2022
Department of Neurology and Neurological Sciences, Stanford University, Stanford, California.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!